{"entity":{"type":"insider","cik":"0001753000","url":"/insider/0001753000","json_url":"/insider/0001753000.json","name":"5AM Opportunities I, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":111,"n_filings":41,"first":"2019-10-09","last":"2026-08-10","span_basis":"filed_date"},"name_variants":[{"name":"5AM Opportunities I, L.P.","source":"filing","n_filings":41,"first_seen":"2019-10-09","last_seen":"2026-08-10"}],"transactions":[{"id":9276041,"accession":"0001231919-26-000854","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52317.0,"shares_display":"52,317","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":358371.45,"total_display":"358,371.45","total_whole":"358,371","shares_owned_after":2783781.0,"shares_owned_after_display":"2,783,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-07","filed_date":"2026-08-10","scope":"insider"},{"id":9276042,"accession":"0001231919-26-000854","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000854","line_url":"/filing/0001231919-26-000854#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; 5AM Ventures V, L.P.; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10494.0,"shares_display":"10,494","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":73458.0,"total_display":"73,458.00","total_whole":"73,458","shares_owned_after":2836098.0,"shares_owned_after_display":"2,836,098","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-06","filed_date":"2026-08-10","scope":"insider"},{"id":6042474,"accession":"0001231919-26-000822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-2","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1718.0,"shares_display":"1,718","price_per_share":6.85,"price_display":"6.85","price_state":"stated","total_value":11768.3,"total_display":"11,768.30","total_whole":"11,768","shares_owned_after":2846592.0,"shares_owned_after_display":"2,846,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-31","filed_date":"2026-08-03","scope":"insider"},{"id":6042470,"accession":"0001231919-26-000822","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000822","line_url":"/filing/0001231919-26-000822#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.","owner_display_name":"ROCKLAGE SCOTT M","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114756.0,"shares_display":"114,756","price_per_share":6.93,"price_display":"6.93","price_state":"stated","total_value":795259.08,"total_display":"795,259.08","total_whole":"795,259","shares_owned_after":2848310.0,"shares_owned_after_display":"2,848,310","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-08-03","scope":"insider"},{"id":5120377,"accession":"0001231919-25-000522","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000522","line_url":"/filing/0001231919-25-000522#line-1","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; Schwab Andrew J.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":8.8,"price_display":"8.80","price_state":"stated","total_value":1760000.0,"total_display":"1,760,000.00","total_whole":"1,760,000","shares_owned_after":2963066.0,"shares_owned_after_display":"2,963,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-14","filed_date":"2025-11-18","scope":"insider"},{"id":4953009,"accession":"0001415889-25-019677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019677","line_url":"/filing/0001415889-25-019677","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; 5AM Partners V, LLC; ROCKLAGE SCOTT M; Schwab Andrew J.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27000.0,"shares_display":"27,000","price_per_share":7.502,"price_display":"7.50","price_state":"stated","total_value":202554.0,"total_display":"202,554.00","total_whole":"202,554","shares_owned_after":3163066.0,"shares_owned_after_display":"3,163,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-11","scope":"insider","n_lines":2},{"id":4320273,"accession":"0001415889-25-018822","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":7.1226,"price_display":"7.12","price_state":"stated","total_value":178065.0,"total_display":"178,065.00","total_whole":"178,065","shares_owned_after":3183131.0,"shares_owned_after_display":"3,183,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-01","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320263,"accession":"0001415889-25-018822","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":6.8127,"price_display":"6.81","price_state":"stated","total_value":170317.5,"total_display":"170,317.50","total_whole":"170,318","shares_owned_after":3201709.0,"shares_owned_after_display":"3,201,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-30","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4320250,"accession":"0001415889-25-018822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-018822","line_url":"/filing/0001415889-25-018822","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Entrada Therapeutics, Inc.","issuer_ticker":"TRDA","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; ROCKLAGE SCOTT M","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":6.91,"price_display":"6.91","price_state":"stated","total_value":518250.0,"total_display":"518,250.00","total_whole":"518,250","shares_owned_after":3220287.0,"shares_owned_after_display":"3,220,287","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":3251890,"accession":"0001415889-24-004111","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004111","line_url":"/filing/0001415889-24-004111","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities I, L.P.; PARMAR KUSH; 5AM Ventures VI, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":825000.0,"shares_display":"825,000","price_per_share":14.9,"price_display":"14.90","price_state":"stated","total_value":12292500.0,"total_display":"12,292,500.00","total_whole":"12,292,500","shares_owned_after":3200634.0,"shares_owned_after_display":"3,200,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider","n_lines":2},{"id":2658941,"accession":"0001415889-24-002295","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002295","line_url":"/filing/0001415889-24-002295","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Ventures VI, L.P.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":3888992.0,"shares_owned_after_display":"3,888,992","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider","n_lines":2},{"id":8681058,"accession":"0001209191-23-050731","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-050731","line_url":"/filing/0001209191-23-050731","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; Schwab Andrew J.; 5AM Partners VI, LLC; PARMAR KUSH; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":197500.0,"shares_display":"197,500","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2962500.0,"total_display":"2,962,500.00","total_whole":"2,962,500","shares_owned_after":4306179.0,"shares_owned_after_display":"4,306,179","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-28","scope":"insider","n_lines":2},{"id":8043975,"accession":"0001209191-23-047514","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-047514","line_url":"/filing/0001209191-23-047514","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; 5AM Partners VI, LLC; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440000.0,"shares_display":"440,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7040000.0,"total_display":"7,040,000.00","total_whole":"7,040,000","shares_owned_after":4470968.0,"shares_owned_after_display":"4,470,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-24","filed_date":"2023-08-28","scope":"insider","n_lines":2},{"id":8219916,"accession":"0001209191-23-024105","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-024105","line_url":"/filing/0001209191-23-024105","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Co-Investors IV, L.P.; ROCKLAGE SCOTT M; 5AM Opportunities I (GP), LLC; 5AM Partners IV, LLC; DIEKMAN JOHN D; Schwab Andrew J.; 5AM Ventures IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16544113.0,"shares_display":"16,544,113","price_per_share":0.12,"price_display":"0.12","price_state":"stated","total_value":1985293.56,"total_display":"1,985,293.56","total_whole":"1,985,294","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-04-10","filed_date":"2023-04-12","scope":"insider","n_lines":3},{"id":6457937,"accession":"0001209191-22-057195","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-057195","line_url":"/filing/0001209191-22-057195","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Partners IV, LLC; Schwab Andrew J.; 5AM Ventures IV, L.P.; DIEKMAN JOHN D; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63773.0,"shares_display":"63,773","price_per_share":2.52,"price_display":"2.52","price_state":"stated","total_value":160707.96,"total_display":"160,707.96","total_whole":"160,708","shares_owned_after":12836489.0,"shares_owned_after_display":"12,836,489","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-15","scope":"insider","n_lines":2},{"id":6457930,"accession":"0001209191-22-057195","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-057195","line_url":"/filing/0001209191-22-057195","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Partners IV, LLC; Schwab Andrew J.; 5AM Ventures IV, L.P.; DIEKMAN JOHN D; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12128.0,"shares_display":"12,128","price_per_share":2.79,"price_display":"2.79","price_state":"stated","total_value":33837.12,"total_display":"33,837.12","total_whole":"33,837","shares_owned_after":12897711.0,"shares_owned_after_display":"12,897,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-14","filed_date":"2022-11-15","scope":"insider","n_lines":2},{"id":6457924,"accession":"0001209191-22-057195","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-057195","line_url":"/filing/0001209191-22-057195","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Partners IV, LLC; Schwab Andrew J.; 5AM Ventures IV, L.P.; DIEKMAN JOHN D; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29380.0,"shares_display":"29,380","price_per_share":3.19,"price_display":"3.19","price_state":"stated","total_value":93722.2,"total_display":"93,722.20","total_whole":"93,722","shares_owned_after":12909354.0,"shares_owned_after_display":"12,909,354","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-11","filed_date":"2022-11-15","scope":"insider","n_lines":2},{"id":6399492,"accession":"0001209191-22-055425","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-055425","line_url":"/filing/0001209191-22-055425","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Co-Investors IV, L.P.; 5AM Opportunities I, L.P.; DIEKMAN JOHN D; Schwab Andrew J.; 5AM Ventures IV, L.P.; 5AM Partners IV, LLC; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M","owner_display_name":"5AM Co-Investors IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10578.0,"shares_display":"10,578","price_per_share":2.72,"price_display":"2.72","price_state":"stated","total_value":28772.16,"total_display":"28,772.16","total_whole":"28,772","shares_owned_after":12937559.0,"shares_owned_after_display":"12,937,559","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-02","filed_date":"2022-11-02","scope":"insider","n_lines":2},{"id":6399486,"accession":"0001209191-22-055425","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-055425","line_url":"/filing/0001209191-22-055425","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Co-Investors IV, L.P.; 5AM Opportunities I, L.P.; DIEKMAN JOHN D; Schwab Andrew J.; 5AM Ventures IV, L.P.; 5AM Partners IV, LLC; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M","owner_display_name":"5AM Co-Investors IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1467.0,"shares_display":"1,467","price_per_share":2.8,"price_display":"2.80","price_state":"stated","total_value":4107.6,"total_display":"4,107.60","total_whole":"4,108","shares_owned_after":12947714.0,"shares_owned_after_display":"12,947,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-01","filed_date":"2022-11-02","scope":"insider","n_lines":2},{"id":6399481,"accession":"0001209191-22-055425","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-055425","line_url":"/filing/0001209191-22-055425","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Co-Investors IV, L.P.; 5AM Opportunities I, L.P.; DIEKMAN JOHN D; Schwab Andrew J.; 5AM Ventures IV, L.P.; 5AM Partners IV, LLC; 5AM Opportunities I (GP), LLC; ROCKLAGE SCOTT M","owner_display_name":"5AM Co-Investors IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42164.0,"shares_display":"42,164","price_per_share":2.78,"price_display":"2.78","price_state":"stated","total_value":117215.92,"total_display":"117,215.92","total_whole":"117,216","shares_owned_after":12949122.0,"shares_owned_after_display":"12,949,122","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-31","filed_date":"2022-11-02","scope":"insider","n_lines":2},{"id":6186191,"accession":"0001209191-22-053401","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-053401","line_url":"/filing/0001209191-22-053401","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"scPharmaceuticals Inc.","issuer_ticker":"SCPH","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"Schwab Andrew J.; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.; 5AM Ventures IV, L.P.; 5AM Partners IV, LLC; 5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; DIEKMAN JOHN D","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":562466.0,"shares_display":"562,466","price_per_share":4.09,"price_display":"4.09","price_state":"stated","total_value":2300485.94,"total_display":"2,300,485.94","total_whole":"2,300,486","shares_owned_after":2231601.0,"shares_owned_after_display":"2,231,601","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-10","filed_date":"2022-10-11","scope":"insider","n_lines":3},{"id":6186180,"accession":"0001209191-22-053401","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-053401","line_url":"/filing/0001209191-22-053401","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"scPharmaceuticals Inc.","issuer_ticker":"SCPH","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"Schwab Andrew J.; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.; 5AM Ventures IV, L.P.; 5AM Partners IV, LLC; 5AM Opportunities I (GP), LLC; 5AM Opportunities I, L.P.; DIEKMAN JOHN D","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37534.0,"shares_display":"37,534","price_per_share":5.02,"price_display":"5.02","price_state":"stated","total_value":188420.68,"total_display":"188,420.68","total_whole":"188,421","shares_owned_after":2688014.0,"shares_owned_after_display":"2,688,014","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-06","filed_date":"2022-10-11","scope":"insider","n_lines":3},{"id":6517774,"accession":"0001209191-22-050387","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-050387","line_url":"/filing/0001209191-22-050387","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures IV, L.P.; Schwab Andrew J.; 5AM Opportunities I, L.P.; 5AM Partners IV, LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.; 5AM Opportunities I (GP), LLC; DIEKMAN JOHN D","owner_display_name":"5AM Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":351.0,"shares_display":"351","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":614.25,"total_display":"614.25","total_whole":"614","shares_owned_after":12989599.0,"shares_owned_after_display":"12,989,599","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-16","filed_date":"2022-09-16","scope":"insider","n_lines":2},{"id":6517766,"accession":"0001209191-22-050387","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-050387","line_url":"/filing/0001209191-22-050387","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures IV, L.P.; Schwab Andrew J.; 5AM Opportunities I, L.P.; 5AM Partners IV, LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.; 5AM Opportunities I (GP), LLC; DIEKMAN JOHN D","owner_display_name":"5AM Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":272750.0,"shares_display":"272,750","price_per_share":1.81,"price_display":"1.81","price_state":"stated","total_value":493677.5,"total_display":"493,677.50","total_whole":"493,678","shares_owned_after":12989936.0,"shares_owned_after_display":"12,989,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-16","scope":"insider","n_lines":2},{"id":6517760,"accession":"0001209191-22-050387","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-050387","line_url":"/filing/0001209191-22-050387","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Ventures IV, L.P.; Schwab Andrew J.; 5AM Opportunities I, L.P.; 5AM Partners IV, LLC; ROCKLAGE SCOTT M; 5AM Co-Investors IV, L.P.; 5AM Opportunities I (GP), LLC; DIEKMAN JOHN D","owner_display_name":"5AM Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":285067.0,"shares_display":"285,067","price_per_share":1.94,"price_display":"1.94","price_state":"stated","total_value":553029.98,"total_display":"553,029.98","total_whole":"553,030","shares_owned_after":13251776.0,"shares_owned_after_display":"13,251,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-14","filed_date":"2022-09-16","scope":"insider","n_lines":2},{"id":6893700,"accession":"0001209191-22-049237","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-049237","line_url":"/filing/0001209191-22-049237","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Pear Therapeutics, Inc.","issuer_ticker":"PEAR","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; Schwab Andrew J.; 5AM Opportunities I (GP), LLC; DIEKMAN JOHN D; 5AM Co-Investors IV, L.P.; 5AM Ventures IV, L.P.; ROCKLAGE SCOTT M; 5AM Partners IV, LLC","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":304322.0,"shares_display":"304,322","price_per_share":1.81,"price_display":"1.81","price_state":"stated","total_value":550822.82,"total_display":"550,822.82","total_whole":"550,823","shares_owned_after":13525440.0,"shares_owned_after_display":"13,525,440","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-08","filed_date":"2022-09-08","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2022-09-08|6893695","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001689375","name":"Entrada Therapeutics, Inc.","url":"/issuer/0001689375","role":"Ten percent owner","n_filings":6,"first_seen":"2021-11-04","last_seen":"2026-08-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"Enliven Therapeutics, Inc.","url":"/issuer/0001672619","role":"Ten percent owner","n_filings":4,"first_seen":"2023-08-28","last_seen":"2024-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001835567","name":"Pear Therapeutics, Inc.","url":"/issuer/0001835567","role":"Ten percent owner","n_filings":6,"first_seen":"2022-08-18","last_seen":"2023-04-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001604950","name":"scPharmaceuticals Inc.","url":"/issuer/0001604950","role":"Ten percent owner","n_filings":3,"first_seen":"2022-04-13","last_seen":"2022-10-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001868734","name":"CinCor Pharma, Inc.","url":"/issuer/0001868734","role":"Ten percent owner","n_filings":2,"first_seen":"2022-01-13","last_seen":"2022-08-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Ten percent owner","n_filings":4,"first_seen":"2021-08-04","last_seen":"2022-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001817229","name":"Vor Biopharma Inc.","url":"/issuer/0001817229","role":"Ten percent owner","n_filings":2,"first_seen":"2021-02-09","last_seen":"2021-11-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner","n_filings":5,"first_seen":"2019-10-31","last_seen":"2021-11-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001445499","name":"IMPEL NEUROPHARMA INC","url":"/issuer/0001445499","role":"Ten percent owner","n_filings":1,"first_seen":"2021-04-29","last_seen":"2021-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001722271","name":"Akouos, Inc.","url":"/issuer/0001722271","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-02","last_seen":"2020-12-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001676725","name":"IDEAYA Biosciences, Inc.","url":"/issuer/0001676725","role":"Ten percent owner","n_filings":1,"first_seen":"2020-11-13","last_seen":"2020-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001781983","name":"Aprea Therapeutics, Inc.","url":"/issuer/0001781983","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2019-10-09","last_seen":"2020-10-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001753000","retrieved_at":"2026-08-22T19:33:38+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}